Multidisciplinary Approaches to HIV-Associated Comorbidities and Prioritizing Intervention Targets (R01 Clinical Trial Not Allowed)
The summary for the Multidisciplinary Approaches to HIV-Associated Comorbidities and Prioritizing Intervention Targets (R01 Clinical Trial Not Allowed) grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact.
If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Multidisciplinary Approaches to HIV-Associated Comorbidities and Prioritizing Intervention Targets (R01 Clinical Trial Not Allowed): Basic research in the area of HIV-associated comorbidities has generally focused on the analysis of a pathway or a potential mechanism that contributes to the development of a single, specific HIV-associated comorbidity or end-organ disease. However, evidence indicates that there could be shared biological mechanisms that underlie the development of certain comorbidities, especially in the context of HIV infection. Targeting these mechanisms may not only impact HIV-associated comorbidities, but also have an impact on HIV cure and help elucidate underlying mechanisms of HIV disease pathogenesis. Through the formation of multidisciplinary teams, this initiative aims to uncover the pathophysiologic mechanisms that drive biological aging and age-related comorbidities in people living with HIV. This Funding Opportunity Announcement (FOA) seeks applications for comprehensive systems biology studies using multidisciplinary team science to identify common, overlapping etiologies of HIV-associated comorbidities. Ultimately, the goal is to identify targets for intervention to mitigate multiple heart, lung, blood, and sleep (HLBS)-related comorbidities associated with HIV infection.
Federal Grant Title: | Multidisciplinary Approaches to HIV-Associated Comorbidities and Prioritizing Intervention Targets (R01 Clinical Trial Not Allowed) |
Federal Agency Name: | National Institutes of Health (HHS-NIH11) |
Grant Categories: | Health |
Type of Opportunity: | Discretionary |
Funding Opportunity Number: | PAR-21-027 |
Type of Funding: | Grant |
CFDA Numbers: | 93.233, 93.837, 93.838, 93.839, 93.840 |
CFDA Descriptions: | Information not provided |
Current Application Deadline: | January 7th, 2023 |
Original Application Deadline: | January 7th, 2023 |
Posted Date: | September 30th, 2020 |
Creation Date: | September 30th, 2020 |
Archive Date: | February 12th, 2023 |
Total Program Funding: | |
Maximum Federal Grant Award: | $480,000 |
Minimum Federal Grant Award: | |
Expected Number of Awards: | |
Cost Sharing or Matching: | No |
Last Updated: | September 30th, 2020 |
- Applicants Eligible for this Grant
- State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
- Additional Information on Eligibility
- Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
- Link to Full Grant Announcement
- http://grants.nih.gov/grants/guide/pa-files/PAR-21-027.html
- Grant Announcement Contact
- NIH OER Webmaster
[email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster - Similar Government Grants
- • Advancing HIV service delivery through pharmacies and pharmacists (R01 Clinical Trial Opti...
- • NHLBI Emerging Investigator Award (EIA) (R35 Clinical Trial Optional)
- • NHLBI Outstanding Investigator Award (OIA) (R35 Clinical Trial Optional)
- • Interventions to Reduce Sleep Health Disparities (R01 - Clinical Trials Optional)
- • Cell and Gene Therapies for HIV Cure: Developing a Pipeline (P01 Clinical Trial Not Allowe...
- • Ancillary Studies in Clinical Trials (R01)
- • Opportunity PA-08-021
- • Research Demonstration and Dissemination Grants (R18)
- More Grants from the National Institutes of Health
- • Hazardous Materials Worker Health and Safety Training (U45 Clinical Trials Not Allowed)
- • Lasker Clinical Research Scholars Program (Si2/R00 Clinical Trial Optional)
- • Type 1 Diabetes TrialNet Clinical Network Hub (U01 Clinical Trial Not Allowed)
- • Advancing HIV service delivery through pharmacies and pharmacists (R21 Clinical Trial Opti...
- • Advancing HIV service delivery through pharmacies and pharmacists (R01 Clinical Trial Opti...